ストックスクリーナーアプリを入手
9.01
11.10%
0.90
アフターアワーズ：
9.01
前日終値:
$8.11
開ける：
$8.15
24時間の取引高:
1.36M
Relative Volume:
1.60
時価総額：
$455.13M
収益：
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.7129
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+2.15%
1か月 パフォーマンス:
+5.13%
6か月 パフォーマンス:
+23.93%
1年 パフォーマンス:
-22.73%
1日の値動き範囲:
$8.07
$9.11
1週間の範囲:
$7.8298
$9.11
52週間の値動き範囲:
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.01 | 439.98M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
| 2025-02-07 | 再開されました | Raymond James | Outperform |
| 2024-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-06-07 | 開始されました | Goldman | Buy |
| 2024-03-11 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 再開されました | Raymond James | Outperform |
| 2023-11-01 | 開始されました | Stifel | Buy |
| 2023-06-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Wedbush | Neutral |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-14 | 再開されました | Raymond James | Outperform |
| 2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-05-09 | 繰り返されました | Barclays | Overweight |
| 2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 開始されました | Mizuho | Neutral |
| 2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay - insights.citeline.com
Delay hits Regenxbio BLA review - The Pharma Letter
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment - BioPharm International
What recovery options are there for REGENXBIO Inc.July 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
FDA delays decision on Regenxbio gene therapy - statnews.com
Can trapped investors hope for a rebound in REGENXBIO Inc.Market Volume Summary & Stepwise Entry/Exit Trade Alerts - Newser
Regenxbio stock steady as FDA extends RGX-121 review timeline - Investing.com
Regenxbio Inc. shares rise 1.49% premarket after FDA review extension for RGX-121. - AInvest
Regenxbio stock holds steady as FDA extends review of Hunter syndrome gene therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Regenxbio Says FDA Extends Review Timeline for RGX-121 - MarketScreener
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for Gene Therapy Commercialization - AInvest
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II - Citizen Tribune
FDA Extends Review for RegenXBio’s RGX-121 Therapy - TipRanks
FDA delays decision on Regenxbio’s Hunter syndrome gene therapy by three months - Endpoints News
REGENXBIO Inc. Facing Inflection Point in Trend AnalysisJuly 2025 WrapUp & Verified High Yield Trade Plans - kangso.co.kr
Is a relief rally coming for REGENXBIO Inc. holdersMarket Sentiment Summary & Reliable Price Action Trade Plans - Newser
How REGENXBIO Inc. stock performs during market volatility2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Will breakout in REGENXBIO Inc. lead to full recovery2025 AllTime Highs & Verified Momentum Stock Alerts - Newser
What candlestick patterns are forming on REGENXBIO Inc.July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
Using data tools to time your REGENXBIO Inc. exitMarket Rally & Daily Stock Trend Watchlist - Newser
Can REGENXBIO Inc. hit a new high this month2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser
Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Are Options Traders Betting on a Big Move in Regenxbio Stock? - Yahoo Finance
What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
Regenxbio Inc (RGNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):